SIRIO Pharma opens multimillion gummy production plant18 Oct 2018
The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.
Sirio Pharma has announced the opening of a gummy production plant at its new development and manufacturing facility in Ma’anshan (300 km West of Shanghai, China). This announcement comes 11 years after SIRIO opened its first gummy facility. The new site will be built in several phases and form a ‘Centre of Excellence’ covering an enormous 240,000 m2.
Phase Ⅰ of the site’s construction has just been completed and features a 26,000sqm gummy production plant and its associated building – designed to expedite development and manufacturing of gummy formulations for global customers.
“In the US and Europe in particular, there is a significant growth potential in gummy formulations – as they are seen as a more consumer-friendly dosage form. For many of the branded firms looking to enter this market early with customized formulations, we offer clear advantages. We can expedite development and even offer taste testing options during formulation. Alternatively, we also offer ready-to-go formulations for companies that are looking to enter the market quickly – because we have one of the largest ranges of existing gummy formulations of any global business. But as consumers become more discerning, we anticipate branded companies will increasingly need specialist gummy development partners and capabilities,” said Rui Yang, CSO of SIRIO Pharma.
The gummy production plant features integrated R&D and will increase production capacity to 2.4 billion gummies per year. SIRIO also expanded its ability to make innovative products such as liquid-filled, centre-filled, swirled and multicoloured gummies. In addition, SIRIO has hundreds of standard gummy formulation options suitable for market launch in the US and EU, and vegetarian options including carrageen and pectin, as well as sugar-free and low-sugar options.
“The advantage of running an integrated site is that we can develop a much more tailored product for customers, while also expediting development timelines, thanks to a large team of in-house gummy specialists - more than 10 scientists and formulation engineers dedicated to gummies. We anticipate exponential growth for the gummy lines in 2019. And obviously, with the new capacity we have, we can supply even for the largest of nutraceutical brands,” said Rui Yang, CSO of SIRIO Pharma.
Loren Israelsen, President, United Natural Products Alliance, on his recent visit to the new facility commented: “I have toured scores of dietary supplement factories around the world, but few equal Sirio's new gummy facility in terms of technology, state-of-the-art design and engineering, robotics, and R&D capabilities. This facility boasts world-class R&D and manufacturing and will help customers innovate new formulations for the fast-growing gummy market."
FDA Approves rfxcel for Verification Router Service (VRS) Pilot
15 Aug 2019
rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.Read more
rfxcel Awarded ISO 9001:2015 Certification
14 Aug 2019
rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.Read more
How real-world data can revolutionise drug development
9 Aug 2019
Utilising the current data environment and its data pools for the benefit of advancing research.Read more
Using mobile phones to fight Alzheimer’s disease
8 Aug 2019
Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.Read more
Automation-compatible prepared culture media plate technology
6 Aug 2019
Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.Read more
Researchers develop 3D printed ingestible pill
4 Aug 2019
Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.Read more
Needle free: Erase wrinkles without injection
15 Jul 2019
Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06Read more
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Cyclolab Ltd strengthens its position in the market
1 Jul 2019
Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation